Liver disease represents a serious risk factor for patients requiring anesthesia and surgery. Even subclinical liver disease increases perioperative morbidity and mortality. Perioperative renal dysfunction and failure have similar implications. Thus, detection of early hepatic and renal dysfunction and monitoring of their progress is essential. This article discusses methods for monitoring hepatic and renal function in patients who have high risk for liver or renal injury in the perioperative period.
Caring for a patient at the end of life requires a thorough understanding of the patient's disease and a detailed investigation into all domains of the patient's being. The patient's goals of care should be revealed, and the interdisciplinary team must work together to provide the patient with maximal care to ensure the best possible quality of life. We must devise a comprehensive and flexible plan so that any anticipated issues may be resolved quickly. As Sir William Osler stated, our goal as physicians is "to cure sometimes, to relieve often, to comfort always."
Resolvins and protectins are new families consisting of distinct chemical series of lipid-derived mediators, each with unique structures and apparent complementary anti-inflammatory actions. Both families of compounds, Rv and protectins, are also generated when aspirin is given in mammalian systems in their respective epimeric forms. The resolvins and protectins each dampen inflammation and PMN-mediated injury from within, which is a key culprit in many common human diseases. The results of these initial studies underscore the roles of resolvins and protectins in inflammation resolution as well as catabasis and spotlight the therapeutic potential for this new arena of immunomodulation and host protection. It is likely that the resolvins, protectins, and their AT-related forms may play roles in other tissues and organs. Moreover, it is noteworthy that fish (eg, trout) generate lipoxygenase products such as LXAs from endogenous EPA and also biosynthesize RvDs and protectins from endogenous DHA. Taken together, these findings suggest that these novel lipid mediators (eg, resolvins and protectins) are conserved in evolution as self-protective and host-protective chemical mediators. In view of the essential roles of DHA and EPA in human biology and medicine uncovered to date, the physiologic relevance of the resolvins and protectins is likely to extend beyond our current appreciation.
There is a strong possibility that the risk from anesthesia and surgery carries over from the immediate perioperative period to more remote time points. This extended risk seems to influence the progression, severity, and complication rate of certain chronic illnesses, such as vascular heart disease and some of the malignancies, although other disease processes might be affected as well. With the recognition that the perioperative process could be responsible for later adverse events comes the need to reassess existing patient safety models, because some of the risk could be preventable. To confront these challenges, it is necessary to understand the underlying biology of this association, and immunology should be particularly helpful in this pursuit. It will be of special importance to integrate our knowledge of the host immune response to anesthesia and surgery with the recent revelations on the role of immunity in the progression of many of the chronic diseases. Additionally, we need to examine how genetic diversity or acquired defects alter the immune response to tissue injury and infection so that we can improve risk stratification and preemptive therapies. In the meantime, we must strive to improve short- and long-term outcomes by expanding our efforts to reduce disease activity preoperatively, to control the surgical stress response and infection rate, and to use tissue-preserving surgical techniques. Long-term patient safety after anesthesia and surgery is not a specialty-by-specialty endeavor; it requires a highly collaborative, institutional, and national effort to foster innovative research and health care process improvements.
Cardiac complications continue to compose a major proportion of serious postoperative morbidity and mortality, and it is appropriate, therefore, that this area has received a lot of attention in the search for pharmacologic modulation of surgical outcomes. Despite numerous studies, conclusive data does not exist, making it difficult to recommend a course of action. beta-blockade has not only made it into national protocols, but is even considered as a quality assessment measure. However, the data are not quite as conclusive as it may sometimes appear. There have been few studies, with a small number of negative outcomes, and, at times, significant methodological concerns. The positive outcomes of meta-analyses rest essentially on a single trial in a highly selected patient population. Although use of beta-blockers in patients who have documented coronary artery disease and are undergoing major vascular procedures appears supported, it is premature to recommend beta-blockade for all patients with cardiac risk. Because these drugs are not without risks, it might be advisable to be restrained in their use until the results of the large-scale randomized POISE trial are available. For clonidine and statins, the data are even more tenuous, and largely based on retrospective reviews (with the exception of postprocedure use of statins, which is well supported). Here again, the results of large-scale prospective trials must become available before recommendations can be made. Finally, promising data indicate that it might be possible to modulate by pharmacologic means the neurocognitive decline that is frequently associated with cardiac surgery, and which is often considered by patients to be the most troublesome complication of the intervention.
A systematic literature review identified qualitative studies of issues important to older people near the end of their lives, to develop a model of the illness experience near the end of life based on the views of older people. Six elements were identified from 40 studies that comprise a core domain of the experience of illness while dying: burden, suffering, hope, dignity, decision making, and control and autonomy. These elements were interwoven with three main themes: contextual factors, perceptions and concerns, and response to illness. Collectively, the core domain and the three themes comprise a model of the experience of illness near the end of life.
Surgical and medical emergencies and treatments are still affected by an unacceptably high rate of morbidity and mortality. Sepsis is the most common medical and surgical complication and the tenth most common cause of death. Antibiotics and antagonists and inhibitors of proinflammatory cytokines have not met expectations. Selective bowel decontamination is no longer a treatment option. After more than 30 randomized clinical trials and 30 years of dedicated efforts to combat sepsis by the use of various combinations of antibiotics, we seem ready to conclude that the vigorous use of antibiotics does not significantly reduce mortality in critically ill patients. Side effects and price constitute important obstacles, especially when it comes to use of cytokine antagonists and inhibitors.
Symptom management requires an understanding of the likely cause of the symptom in the individual patient, comprehensive assessment, and evidence-based interventions. This article explores the management strategies for common symptoms encountered in palliative care practice. Stomatitis, xerostomia, dysphagia, nausea and vomiting, anorexia, constipation, dyspnea, and fatigue are among the symptoms reviewed.
As medical science progresses and the life spans of patients with serious illnesses increase, the process that leads to death is becoming more feared than death itself. This fear is particularly intense in technologically advanced cultures with access to advanced medical care. The lives of patients who previously would have died rapidly are now often extended. As a result, images of suffering, such as dying in isolation and experiencing great pain, often are at the forefront of concerns about those struggling with terminal illnesses. This article provides medical practitioners with an overview of the issues and symptoms common in terminal illness, to help them work most effectively with their mental health colleagues.
The expense associated with modern heath care in the United States is very high, in excess of 15% of the GDP, continues to grow and has become a significant public policy issue. New technologies, defined as all drugs, devices, procedures, and organizational systems, are major contributors to rising health care costs. The use of health technology assessment tools can assist those in leadership positions in making rational decisions as to which new technologies to adopt. The classical approach is to use data from prospective, randomized, clinical trials that compare the outcomes of those treated with the new technology and the accepted therapy. Using this information and detailed economic data, the cost-effectiveness ratio can be determined. The accepted metrics are either dollars per life year saved or dollars per quality-adjusted life year saved. If the new medical intervention costs less than $50,000 to 80,000 dollars per life year saved, it is considered to be cost-effective and worthy of adoption. This kind of analysis is complex and expensive. In addition, the required information is not always available, limiting the applicability of this approach. Finally, the economic analysis often includes down-stream expense and benefit not relevant from a medical center perspective. Another approach is to focus the analysis to what impacts the medical center. This includes determining whether the technology has received the necessary approvals and has been shown to be effective, to improve health outcomes, to be at least as effective as standard therapy, and to be achievable outside the investigative setting. A fiscal analysis also must be done to determine what will it cost to acquire and operate the technology, what are the anticipated patient volumes and payer mix, and what will be the down-stream consequences to the medical center. If the process concludes that the technology works, makes a positive difference to patient care, and is fiscally and operationally acceptable, it should be purchased. After the technology has been installed and has been used, a postimplementation review should be done. This review should go over the same attributes that led to the decision to purchase. It should be determined whether the expected patient volumes, outcomes, income, and expenses were seen. If not, the technology assessment process should be refined to make better decisions in the future. Finally, if the results are at a substantial negative variance from what was anticipated, abandoning the technology should be considered. Anesthesiology either directly controls or indirectly influences a significant portion of medical technology in every medical center. Therefore, the processes that have been discussed in this article should be used by the department of anesthesiology to assure optimal patient care and the fiscal stability of the organization.
This article describes the grieving process. It begins by delineating the nature of grief, noting the ways that grief may be experienced in both sudden loss and in more protracted illness and then explores the nature and process of grief, reviewing current models and research on the experience of mourning. Finally, the discussion examines the research on caregiver grief, noting that grief in health care professionals is often disenfranchised, yet the holistic treatment of individuals with disease begins with an acknowledgment that loss is a constant companion to illness, for patients, families, and health care professionals alike.
The spiritual agenda for the dying presumes a willingness to face the reality of imminent death. It also depends on support from caregivers who will encourage whatever agency is possible for the one who is dying. The spiritual practices that will enhance agency for the dying include remembering, thanking, relinquishing, waiting, and trusting. The absence of abandonment and the dependable presence of caregivers are essential to create communities and relationships in which hope can be found and sustained.
The prevalence of the neurodegenerative disorders is increasing as life expectancy lengthens, and there exists concern that environmental influences may contribute to this increase. These disorders are varied in their clinical presentation, but appear to have a common biophysical initiation. At this level, it is both plausible and now proven that anesthetics can enhance aggregation of some disease-causing proteins. Although data in support of an interaction in animal models are still lacking, data from clinical studies indicate an association, which provides further cause for concern. Many opportunities exist for rapid progress at all levels on defining whether anesthetics do indeed contribute to the pathogenesis of these progressive, debilitating disorders.
The anesthetic management of the MO patient requires an important focus on a number of issues beginning with a careful preoperative evaluation and synthesizing pre-existing disease processes with the anesthetic management plan. The common misperception that all MO patients are "full stomach" has been challenged and may be a nonissue. New approaches to pre-oxygenation to lessen the likelihood of desaturation during apnea may be a valuable tool if difficulty is encountered in tracheal intubation. In addition, promising results have been demonstrated with the use of the ILMA for ventilation and for blindly establishing tracheal tube placement. Proper patient positioning is essential to aid in successful intubation when a laryngoscope is employed. Intraoperative anesthetic management can be guided with a processed electroencephalogram monitor to help improve emergence and to enhance wakefulness in the PACU. Careful consideration must be given to postoperative analgesic needs by minimizing the use of opioids and employing nonopioid analgesics including NSAIDs, alpha2-adrenergic agonists, and low doses of ketamine.
Monitoring hemostasis is now possible by different modalities, of which the point of care devices seem most helpful to the clinician in the operating room. Most of these monitors are being used in the cardiac population, and their significance in other fields remains to be assessed.
With advancing age, interpatient variability increases. Physiologic and pathologic apoptosis progress at widely different rates in each organ system in each person. The effect of any disease on an individual depends on the genetic makeup, social and environmental insults, and adequacy of and compliance with medical therapy. Time spent interviewing, examining, and preparing elderly patients preoperatively pays dividends intra- and postoperatively, with fewer "rescue requiring events," fewer "failures to rescue," lower observed-to expected morbidity and mortality ratios, better patient care, and greater patient and professional satisfaction. Elderly patients will require anesthetic services in greater numbers in the years to come. The baby boomers are coming. Are you ready for them?
The present understanding of the coagulation process emphasizes the final common pathway and the proteolytic systems that result in the degradation of formed clots and the prevention of unwanted clot formations, as well as a variety of defense systems that include tissue repair, autoimmune processes, arteriosclerosis, tumor growth, the spread of metastases, and defense systems against micro-organisms. This article discusses diagnosis and management of some of the most common bleeding disorders. The goals are to provide a simple guide on how best to manage patients afflicted with congenital or acquired clotting abnormalities during the perioperative period, present a brief overview of the methods of testing and monitoring the coagulation defects, and discuss the appropriate pharmacologic or blood component therapies for each disease.
Acute and chronic psychosocial stress leads to the activation of leukocytes and inflammatory reflexes, resulting in metabolic changes. These cellular responses contribute to the finding, that psychosocial stress is an independent predictor of mortality. This article links the current knowledge on inflammatory reactions induced by psychosocial stress to metabolic and vascular disease.
Ethical concerns are common in palliative care settings. Rather than provide an exhaustive list of possible ethical problems one may come upon, this article describes areas of concern that are frequently encountered by perioperative health care providers, especially anesthesiologists, in the palliative care arena.
Surgical site infections are among the most common serious perioperative complications. Infections are established during a decisive period that lasts a few hours after contamination. Adequacy of host immune defenses is the primary factor that determines whether inevitably wound contamination progresses into a clinical infection. As it turns out, many determinants of infection risk are under the direct control of anesthesiologists; factors that are at least as important as prophylactic antibiotics. Major outcome studies demonstrate that the risk of surgical wound infection is reduced threefold simply by keeping patients normothermic. Infection risk is reduced by an additional factor of two by if supplemental oxygen is provided (80% versus 30%) during surgery and for the initial hours after surgery. The contribution, if any, of other factors including, tight glucose control, fluid management, and mild hypercapnia have yet to be suitably tested.
